首页 | 官方网站   微博 | 高级检索  
     

金糖宁胶囊联合卡格列净治疗2型糖尿病的临床研究
引用本文:胡晓艺,范莹,张方,曾菲,唐榕,汤敏. 金糖宁胶囊联合卡格列净治疗2型糖尿病的临床研究[J]. 现代药物与临床, 2020, 35(5): 971-974
作者姓名:胡晓艺  范莹  张方  曾菲  唐榕  汤敏
作者单位:中国人民解放军西部战区空军医院药剂科, 四川 成都 610000;四川口腔医院药剂科, 四川 成都 610000;中国人民解放军西部战区空军医院内分泌科, 四川 成都 610000
摘    要:目的探讨金糖宁胶囊联合卡格列净治疗2型糖尿病的临床疗效。方法选取2018年6月—2019年6月在中国人民解放军西部战区空军医院进行治疗的88例2型糖尿病患者,随机分为对照组和治疗组,每组各44例。对照组口服卡格列净片,0.1g/次,1次/d,餐前服用;治疗组在对照组治疗基础上口服金糖宁胶囊,4粒/次,3次/d。两组均治疗4周后进行效果对比。观察两组的临床疗效,比较两组治疗前后空腹血糖(FBG)、餐后2 h血糖(2h PG)、糖化血红蛋白(HbA1c)、胰岛素(FINS)相关血清学指标、HOMA-β和HOMA-IR的变化情况。结果治疗后,对照组和治疗组的总有效率分别是81.82%、97.73%,两组比较差异有统计学意义(P<0.05)。经治疗,两组FPG、2h PG、HbAlc及FINS水平均较治疗前显著降低(P<0.05);治疗后,治疗组这些血糖相关指标较对照组下降更显著(P<0.05)。经治疗,两组同型半胱氨酸(Hcy)、γ-谷氨酰转移酶(γ-GT)、白细胞介素-1β(IL-1β)、人颗粒蛋白前体(PGRN)、富含半胱氨酸的酸性分泌蛋白(SPARC)、皮质醇(Cor)水平均显著下降(P<0.05);且治疗后治疗组这些血清学指标显著低于对照组(P<0.05)。经治疗,两组HOMA-β显著升高,而HOMA-IR显著降低(P<0.05);治疗后,治疗组HOMA-β显著高于对照组,而HOMA-IR低于对照组(P<0.05)。结论金糖宁胶囊联合卡格列净治疗2型糖尿病具有较好的临床疗效,能有效控制血糖,降低机体相关血清因子水平,提高胰岛素敏感性,改善机体胰岛素抵抗,具有一定的临床推广应用价值。

关 键 词:金糖宁胶囊  卡格列净片  2型糖尿病  空腹血糖  餐后2  h血糖  糖化血红蛋白  胰岛素  同型半胱氨酸  Γ-谷氨酰转移酶  白细胞介素-1Β  人颗粒蛋白前体  富含半胱氨酸的酸性分泌蛋白  皮质醇
收稿时间:2019-10-14

Clinical study on Jintangning Capsules combined with Canagliflozin Tablets in treatment of type 2 diabetes
HU Xiao-yi,FAN Ying,ZHANG Fang,ZENG Fei,TANG Rong,TANG Min. Clinical study on Jintangning Capsules combined with Canagliflozin Tablets in treatment of type 2 diabetes[J]. Drugs & Clinic, 2020, 35(5): 971-974
Authors:HU Xiao-yi  FAN Ying  ZHANG Fang  ZENG Fei  TANG Rong  TANG Min
Affiliation:Department of Pharmacy, Air Force Hospital of the PLA Western Theater Command, Chengdu 610000, China;Department of Pharmacy, Sichuan Dental Hospital, Chengdu 610000, China; Department of Endocrinology, Western Theater Air Force Hospital, Chengdu 610000, China
Abstract:Objective To explore the clinical efficacy of Jintangning Capsules combined with Canagliflozin Tablets in treatment of type 2 diabetes.Methods 88 Patients with type 2 diabetes who were treated in Air Force Hospital of the PLA Western Theater Command from June 2018 to June 2019 were randomly divided into control(44 cases)and treatment group(44 cases).Patients in the control group were po administered with Canagliflozin Tablet,0.1 g/time,once daily.Patients in the treatment group were po administered with Jintangning Capsules on the basis of the control group,4 grains/time,three times daily.All patients were treated for 4 weeks.The clinical efficacy of the two groups were compared.The changes of fasting blood glucose(FBG),2-hour postprandial blood glucose(2 h PG),glyca1 c(HbA1 c),insulin(FINS),related serological indexes,HOMA-βand HOMA-IR were compared before and after treatment in the two groups.Results After treatment,the total effective rate of the control group and the treatment group was 81.82%and 97.73%,respectively.The difference between the two groups was statistically significant(P<0.05).After treatment,the levels of FPG,2 h PG,Hb Alc and FINS in the two groups were significantly lower than those before treatment(P<0.05).After treatment,these blood glucose related indexes in the treatment group decreased more significan tly than those in the control group(P<0.05).After treatment,Hcy,γ-GT,IL-1β,PGRN,SPARC,and Cor levels in the two groups were significantly decreased(P<0.05).After treatment,the serological indexes of the treatment group were significantly lower than those of the control group(P<0.05).After treatment,HOMA-βsignificantly increased in the two groups,while HOMA-IR significantly decreased in the two groups(P<0.05).After treatment,HOMA-βin the treatment group was significantly higher than that in the control group,while HOMA-IR was lower than that in the control group(P<0.05).Conclusion Jintangning Capsules combined with Canagliflozin Tablets in treatment of type 2 diabetes has good clinical efficacy,and can effectively control blood sugar,reduce the level of related serum factors,and can improve insulin sensitivity and insulin resistance,which has a certain clinical application value.
Keywords:Jintangning Capsules  Canagliflozin Tablets  type 2 diabetes  FBG  2h PG  HbA1c  FINS  Hcy  γ-GT  IL-1β  PGRN  SPARC  Cor
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号